IP Verse

Biogaran opposition analysis

COMPANY ANALYSIS

Latest oppositions filed by Biogaran

Patent Number:
EP3345604
Title:
Nalmefene For Reduction Of Alcohol Consumption In Specific Target Populations
Applicant:
H. LUNDBECK A/S
Opposition Date:
Mar 6, 2024
Patent Number:
EP3578175
Title:
Rapid Dissolution Formulation Of A Calcium Receptor-Active Compound
Applicant:
AMGEN INC.
Opposition Date:
Aug 30, 2023
Patent Number:
EP2653873
Title:
Compositions And Uses For Treating Multiple Sclerosis
Applicant:
BIOGEN IDEC MA INC.
Opposition Date:
Apr 20, 2023
Patent Number:
EP2959894
Title:
S1P Receptor Modulators For Treating Multiple Sclerosis
Applicant:
NOVARTIS AG
Opposition Date:
Jan 13, 2023
Patent Number:
EP2478907
Title:
Methods And Compositions For Treating Cancer
Applicant:
COUGAR BIOTECHNOLOGY, INC.
Opposition Date:
Jan 14, 2022
Patent Number:
EP2234617
Title:
Dosing Regimen Associated With Long Acting Injectable Paliperidone Esters
Applicant:
JANSSEN PHARMACEUTICA NV
Opposition Date:
Dec 23, 2021
Patent Number:
EP3395338
Title:
Rapid Dissolution Formulation Of Cinacalcet Hcl
Applicant:
AMGEN INC.
Opposition Date:
Jan 31, 2020
Patent Number:
EP3260117
Title:
Rapid Dissolution Formulation Of A Calcium Receptor-Active Compound
Applicant:
AMGEN INC.
Opposition Date:
Jan 17, 2020
Patent Number:
EP3395339
Title:
Rapid Dissolution Formulation Of A Cinacalcet Hcl
Applicant:
AMGEN INC.
Opposition Date:
Jan 17, 2020
Patent Number:
EP3395340
Title:
Rapid Dissolution Formulation Of Cinacalcet Hcl
Applicant:
AMGEN INC.
Opposition Date:
Jan 17, 2020

Competitors of Biogaran

AMGEN INC.

AMGEN, INC

NOVARTIS AG

Want to track Biogaran?

Feel free to send us a message here and we will get back to you